Managed Care Considerations and Implementation Strategies for Biosimilars in Oncology

2022 ASH Annual Meeting Coverage—Recent Developments in Diffuse Large B-Cell Lymphoma: Insights and Application for Managed Care

Advances in High-Risk Myelodysplastic Syndromes: Insights and Application for Managed Care With ASH Annual Meeting Coverage

Managed Care Insights on Optimizing the Use of BCMA-Targeted Treatments in Multiple Myeloma

ESMO Congress 2022: Advances and Best Practices for Managed Care Pharmacists in the Treatment of Metastatic Head and Neck Squamous cell Carcinoma

Advances in Prostate Cancer: An Evidence-based Review for Managed Care Professionals

An Article in the American Journal of Managed Care’s Evidence-Based Oncology: Navigating the Complexities of Frontline Immunotherapy in NSCLC

Clinical Conversations With the Cancer Care Team: Discussing the Impact of Social Inequities on Treatment Outcomes in Triple-Negative Breast Cancer

Recognizing Rett Syndrome: Managed Care Insights on Disease Burden

Advancements in Myasthenia Gravis Treatment: Supporting Access Through Value-Based Care Models

Challenges of Treating Epilepsy Syndromes and Opportunities in an Expanding Therapeutic Landscape: A Managed Care Perspective

Challenging the Treatment Paradigm for HER2-low Breast Cancer: Managed Care Perspectives

The Latest on Acute Lymphocytic Leukemia

Developing Clinical Pathways for Treatment of Advanced/Metastatic ccRCC in Managed Care Pharmacy: Opportunities, Challenges, and Best Practices

CAR T-Cell Therapy Advances in Lymphoma: Implications for Managed Care

Targeting the Sickle Cell Disease Cascade and the Shifting Approach to Care

Advancements in Treatment Options for Age-Related Macular Degeneration and Diabetic Macular Edema, featuring a Patient Perspective

Evaluating Novel Nonhormonal Approaches for the Treatment of Menopausal Vasomotor Symptoms

The Evolving Treatment Landscape for HR+/HER2- Breast Cancer: Updates and Considerations for Managed Care

Managed Care Approaches in Optimizing the Impact of PARP Inhibitors on Resource Utilization and Clinical Outcomes in Ovarian Cancer

ROS1-Targeted Treatments in NSCLC: Updates and Best Practices for Managed Care